-+ 0.00%
-+ 0.00%
-+ 0.00%
BioCryst Pharma Announces New Real-World Evidence On Use Of Once-Daily ORLADEYO For Patients With Hereditary Angioedema, Showing Reductions In Hospitalizations And Emergency Department Visits
Share
Listen to the news

—Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO® from another prophylactic therapy—

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of once-daily ORLADEYO® (berotralstat), the first and only targeted oral prophylactic therapy for patients with hereditary angioedema (HAE) aged 2 and older, showing reductions in hospitalizations and emergency department visits following ORLADEYO initiation in patients new to long-term prophylactic therapy (LTP) and in patients switching to ORLADEYO from another LTP.

This practice-informing research will be featured across two poster presentations during the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16. 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending